logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Relation of interferon therapy and hepatocellular carcinoma in Patients with chronic hepatitis C.

    Article - En anglais

    Background 

    The effect of interferon therapy on the incidence of hepatocellular carcinoma in chronic hepatitis C is poorly defined.

    Objective 

    To compare the incidence of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C to that of historical controls and to examine whether response to therapy is related to incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Design : Retrospective cohort study.

    Setting 

    One university hospital and seven university-affiliated hospitals.

    Patients 

    419 consecutive patients with chronic hepatitis C who started interferon therapy between January 1992 and December 1993 (interferon group) and 144 patients with chronic hepatitis C who had liver biopsy between January 1986 and December 1989 and did not receive interferon (controls).

    Intervention 

    Patients in the interferon group received human lymphoblastoid interferon, recombinant interferon-alpha2a, or recombinant interferon-alpha2b for 6 months.

    Measurements 

    The end point was development of hepatocellular carcinoma on abdominal ultrasonography or computed tomography.

    Sustained response was defined as persistent normalization of alanine aminotransferase (ALT) levels during interferon therapy and follow-up.

    Relapse was defined as a normal serum ALT level at the end of treatment with an increase to an abnormal level after cessation of treatment.

    Nonresponse included all other ALT patterns. (...)

    Mots-clés Pascal : Carcinome hépatocellulaire, Association, Hépatite virale C, Virose, Infection, Interféron, Traitement, Etude cohorte, Incidence, Facteur efficacité, Corrélation, Homme, Appareil digestif pathologie, Foie pathologie, Tumeur maligne, Antiviral, Immunothérapie

    Mots-clés Pascal anglais : Hepatocellular carcinoma, Association, Viral hepatitis C, Viral disease, Infection, Interferon, Treatment, Cohort study, Incidence, Effectiveness factor, Correlation, Human, Digestive diseases, Hepatic disease, Malignant tumor, Antiviral, Immunotherapy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0362371

    Code Inist : 002B02Q. Création : 25/01/1999.